NDAORALTABLET
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FARESTON (toremifene citrate) is an oral selective estrogen receptor modulator (SERM) approved for metastatic breast cancer in postmenopausal women. It functions as a nonsteroidal antiestrogen that competes with estrogen for receptor binding in breast tissue, inhibiting tumor growth in hormone-sensitive cancers.
$0.088MPart D
LOE ApproachingDeclining
With LOE approaching and only 85 Part D claims in 2023, this product faces significant generic/competitive erosion; commercial teams are likely in maintenance or transition mode with minimal growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Started Mar 2011
0Risk of Bone Fracture Occurrences
Career Relevance
Working on FARESTON offers limited career growth opportunity due to LOE status and minimal commercial activity; roles are primarily defensive/maintenance-focused with low job opening volume. This assignment may suit professionals seeking stable legacy product experience or those transitioning out of specialty oncology.
Brand Manager
Worked on FARESTON at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.